摘要:
There is disclosed a pharmaceutical combination for lessening or preventing any flush reaction caused by nicotinic acid therapy, the combination comprising nicotinic acid and a nonsteroidal anti-inflammatory drug in an amount effective to inhibit or reduce prostaglandin D 2 (PGD 2 ) synthesis.
摘要:
The present invention refers to O-acyl salicylic acid derivatives (I) bearing a NO donor moiety, a process for their preparation and pharmaceutical compositions containing them. (I) wherein : D is ONO2 or (A).
摘要:
The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases.
摘要:
The present invention is based upon the novel observation of the COX-II-specific inhibitory activity of gamma-tocopherol and that by combining gamma-tocopherol with precursors of connective tissue constituents, injured or degenerated connective tissue, especially of articulated joints of animal patients, may be repaired. The method of the invention for treating a inflammatory disorder of a joint comprises administering to the mammal a pharmaceutical composition comprising an amount of gamma-tocopherol effective in selectively inhibiting cyclooxygenase-2 and at least one compound that elevates the production of a component of connective tissue in an amount effective for the promotion of connective tissue formation. The invention also provides pharmaceutical or veterinary compositions comprising a tocopherol preparation having at least 50% w/w gamma- tocopherol or a derivative thereof and in an amount effective for selectively inhibiting cyclooxygenase-2 in the recipient mammal and at least one compound that elevates the production of a component of connective tissue.
摘要:
The invention describes novel organic nitric oxide enhancing salts of nonsteroidal antiinflammatory drugs (NSAIDs) and novel compositions comprising at least one organic nitric oxide enhancing salt of an NSAID, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides novel compositions and kits comprising at least one organic nitric oxide enhancing salt of an NSAID, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating inflammation, pain and fever; (b) treating gastrointestinal disorders; (c) facilitating wound healing; (d) treating gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; (e) treating inflammatory disease states and/or disorders; (f) treating ophthalmic disorders; (h) treating peripheral vascular diseases; (i) treating diseases resulting from oxidative stress; (j) treating endothelial dysfunctions; and (k) treating diseases caused by endothelial dysfunctions. The organic nitric oxide enhancing compounds that form salts with the NSAIDs are organic nitrates, organic nitrites, nitrosothiols, thionitrites, thionitrates, NONOates, heterocyclic nitric oxide donors and/or nitroxides. The heterocyclic nitric oxide donors are furoxans, sydnonimines, oxatriazole-5-ones and/or oxatriazole-5- imines.
摘要:
What is claimed are compositions for the treatment of psoriasis, eczema and inflammatory conditions of the skin comprising as an active ingredient a therapeutic effective amount of thiamine or its cosmetically and/or toxicologically acceptable salts.
摘要:
The invention provides compositions and methods that employ compounds that can stimulate proliferation of fibroblasts or keratinocytes and/or stimulate production of collagen by fibroblasts. These compositions and methods are useful for treating gum- and skin-related conditions.
摘要:
A method for treating cellular and tissue damage is disclosed. The inventive method comprises the use of 2,3-alkylcarbonyloxybenzoic acid and salts thereof in the prevention and treatment of dysfunction, damage, and/or injuries to organs, tissues and/or cells in human or animal subjects caused by diseases, infections and conditions such as pneumonia, coronavirus, multiple transfusions, trauma, ischemic-reperfusion dysfunctions, stroke, drug overdose, and severe acute respiratory syndrome. The 2,3-alkylcarbonyloxybenzoic acid may be used alone or in combination with other therapeutic agents such as antibiotics. The acid may be administered in any practical delivery form, and in free acid or buffered form.